REXR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
REXR is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is near short-term support and pre-market is green, but the broader setup is mixed: bearish moving averages, a slightly negative MACD, neutral RSI, no bullish proprietary trading signal, and weak sentiment from hedge fund selling. Analyst opinions are still mostly neutral-to-moderately positive, but recent price target cuts show conviction is fading. My direct view: hold and wait for clearer confirmation before buying.
Current price is 35.23 pre-market, up 1.50%, with the stock hovering just above the pivot at 34.651. Short-term momentum is not convincing: MACD histogram is -0.0696 and still negative, RSI_6 is 49.715, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. That structure suggests the stock is still in a weak trend and not yet in a clean uptrend. Near-term levels to watch are support at 33.78 and resistance at 35.522 and 36.06. The stock trend model implies modest near-term upside, but not enough to offset the broader technical weakness.
Recent analyst commentary is not outright bearish: Cantor Fitzgerald still has an Overweight rating, and Evercore upgraded the stock to Outperform earlier in April. The sector backdrop remains favorable thanks to demand from manufacturing and data centers, easing supply, and supply-chain reshoring themes. The stock is also near technical support, and pre-market trading is positive.
No news was reported in the recent week, so there is no fresh event-driven catalyst. Multiple analysts lowered price targets recently, including Baird to $39 from $41 and BofA to $42 from $43, signaling reduced near-term upside expectations. Hedge funds are selling aggressively, insiders are neutral, and options positioning leans bearish. Technically, the trend is still weak and not yet confirming a durable bottom.
No usable latest-quarter financial snapshot was provided because of a data error, so I cannot give a reliable quarter-by-quarter growth read. Based on the analyst notes, Q1 results showed only early signs of improvement and more evidence is still needed for conviction. The latest referenced quarter is Q1 2026.
Analyst sentiment is mixed but currently leaning Neutral. Baird and BofA both cut targets recently while keeping Neutral ratings, which is a mild negative. Cantor Fitzgerald remains Overweight but still lowered its target, and Evercore upgraded the stock to Outperform with a $40 target. Overall, Wall Street pros see some long-term sector strength, but the recent target cuts show they are less confident in near-term upside.
